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TO THE EDITOR
CDKN2A (OMIM 600160) is the major
melanoma susceptibility gene identified
to date, which predisposes to familial
melanoma and multiple primary mela-
noma (MPM). Germline CDKN2A mu-
tations have been detected with a
frequency varying from 5 to 46% in
melanoma families from different coun-
tries (Holland et al., 1995; Walker
et al., 1995; FitzGerald et al., 1996;
Soufir et al., 1998). Different ethnic and
environmental factors might account
for such different percentages. The
majority of CDKN2A germline muta-
tions has been found in exons 1a and 2
of the CDKN2A gene affecting predomi-
nantly the p16INK4A transcript (Stahl et al.,
2004). However, a specific role for the
p14ARF transcript has been suggested by
the identification of a germline deletion
of the CDKN2A gene involving exon 1b
(Hewitt et al., 2002) and of five different
germline mutations at the p14ARF exon
1b splice donor site in familial melanoma
kindreds (Harland et al., 2005).
Three polymorphisms have been
detected in the CDKN2A gene includ-
ing one coding variant (c.442G4A)
localized in exon 2 and two noncoding
variants (c.500C4G and c.540C4T)
localized in the 30 untranslated region.
The c.442G4A variant converts an
alanine (GCG) to a threonine (ACG)
residue at codon 148 (A148T), located
in the fourth ankyrin repeat domain,
and has no recognized effect on
p16INK4A function (Ranade et al.,
1995; Lilischkis et al., 1996). The
A148T allele frequency has been re-
ported to vary from 1.5% in the CEPH
population (Hussussian et al., 1994) to
2% in the Utah population (Kamb et al.,
1994), and it has been recently sug-
gested to be a low penetrance mela-
noma susceptibility allele in a popula-
tion from Poland (Debniak et al., 2005).Abbreviations: CI, confidence interval; MPM, multiple primary melanoma; OR, odds ratio
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The c.500C4G and the c.540C4T
polymorphisms were not shown to be
overrepresented in melanoma patients
(Aitken et al., 1999).
To determine the contribution of the
A148T variant on melanoma risk, we
genotyped this allele in two European
populations from France and Italy. An
overall number of 500 French mela-
noma patients comprising 405 sporadic
melanoma patients, 57 familial mela-
noma patients and 38 sporadic multiple
primary melanoma patients were re-
cruited from the MELAN-COHORT, a
prospective melanoma cohort includ-
ing all melanoma patients from Depart-
ments of Dermatology of different
Hospitals in Paris (Bichat, Percy,
Ambroise Pare´, Henri Mondor, Cochin
and Saint-Louis Hospitals). In addition,
119 Italian sporadic melanoma patients
were enrolled at the Department of
Dermatology of the University of
L’Aquila, L’Aquila, Italy. The control
groups, matched by sex and age (within
71 year) to the case groups, were
recruited among patients affected by
diseases unrelated to melanoma attend-
ing the same Hospitals and were
composed of 143 French and 121
Italian control subjects with no personal
or family history of skin cancer. The
number of common melanocytic nevi
and the presence or absence of clini-
cally atypical nevi and of atypical
mole syndrome were recorded for all
Italian melanoma patients, for 184
French melanoma patients and for all
French and Italian controls through
physical examination by a dermato-
logist. Subjects were classified as
having p50 or 450 common melano-
cytic nevi. A detailed medical and
family history with regard to cuta-
neous and extracutaneous malignant
neoplasms was also obtained. Histo-
pathologic features of melanoma, tu-
mor site, and age at diagnosis were also
recorded.
After genomic DNA extraction from
peripheral blood leukocytes using the
QIAamp Blood Mini Kit (QIAgen GmbH,
Hilden, Germany), the A148T allele was
genotyped using the Taqman SNP
Genotyping Assay–allelic discrimination
method (Applied Biosystems, Foster City,
CA). The study was approved by the
Local Ethical Committees and The
Declaration of Helsinki Principles were
followed. Written informed consent was
obtained from all participants.
The genotype frequency of the
A148T variant in the melanoma and
control groups was compared using w2
test and two-sided P-value. Odd ratios
(OR) were also estimated by comparing
at risk genotypes (homozygotes
AAþheterozygotes AG) versus the ‘‘re-
ference or consensus’’ genotype (homo-
zygotes GG). In addition, in order to
evaluate the risk according to different
age groups, melanoma patients were
divided into two different groups based
on the age at diagnosis: p50 years and
450 years. Genotypes and allele fre-
quency of the A148T allele in the
French and Italian populations are
shown in Table 1. Genotype frequency
in both melanoma groups and both
control groups was in Hardy–Weinberg
equilibrium. The frequency of the mu-
tant allele A was 6.7% in the Italian
melanoma patients and 6.2% in the
corresponding control subjects (OR
1.10, 95% confidence interval (CI)
(0.51–2.37); P¼0.80), 3.4% in the
French melanoma group and 4.2% in
the French controls (OR 0.77, 95% CI
(0.39–0.52); P¼0.46) (Table 1). Three
subjects were homozygotes for the
mutant sequence, including two mela-
noma patients (one in the French
melanoma group and one in the Italian
melanoma group) and one Italian con-
trol subject. An overall significant
statistical difference in the A148T allele
frequency was detected between Italian
and French subjects (P¼0.008).
No association of the A148T allele
with melanoma risk was detected in the
group of patients p50 years of age at
diagnosis (French population: OR 1.53,
95% CI (0.41–1.55); P¼0.44; Italian
population: OR 0.38, 95% CI
(0.11–1.27); P¼0.12). The total number
of common melanocytic nevi and the
presence of clinically atypical nevi were
not associated with the A148T allele
in both populations. In addition, in the
French cohort, the A148T was not
associated with any melanoma sub-
group, that is, sporadic melanoma (allele
frequency 3.4%, P¼0.88), familial mel-
anoma (allele frequency 4.4%, P¼0.9),
and sporadic multiple primary melano-
ma (allele frequency 4%, P¼ 0.96).
The role of the A148T allele in
melanoma has been investigated in a
few studies reporting discordant results
in different series of melanoma patients
(Aitken et al., 1999; Ghiorzo et al.,
1999; Kumar et al., 2001; Bertram
et al., 2002; Debniak et al., 2005)
(Table 2). Ghiorzo et al. (1999) identi-
Table 1. Frequency of the A148T allele in melanoma cases and controls of
a French and an Italian population
No. of subjects Genotype (%) c.442 allele frequency P-value OR (95% CI)
119 Italian patients A/A 1 (0.84) 6.72% 0.81 1.10 (0.51–2.37)
G/A 14 (11.76)
G/G 104 (87.4)
121 Italian controls A/A 1 (0.83) 6.2%
G/A 13 (10.74)
G/G 107 (88.43)
500 French patients A/A 1 (0.2) 3.4% 0.46 0.77 (0.39–1.52)
G/A 32 (6.4)
G/G 467 (93.4)
143 French controls A/A 0 (0.0) 4.2%
G/A 12 (8.4)
G/G 131 (91.6)
CI, confidence interval; OR, odds ratio.
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fied the A148T polymorphism in five of
14 Italian melanoma family members
(OR 1.9, 95% CI (0.4–5.6)) with no
segregation of this variant with the
melanoma phenotype. In a subsequent
study, the A148T was detected in 4.9%
of adults from 179 English families with
the atypical nevus phenotype and/or a
family history of melanoma and in
5.2% of controls (Bertram et al.,
2002). Both studies did not show
evidence for the A148T variant as a
melanoma susceptibility allele.
In a large cohort of Polish patients, the
A148T allele has been shown to be
associated with an increased risk of
cutaneous melanoma being detected
in 7% of melanoma patients versus
2.89% of the control subjects with an
OR of 2.529 (95% CI 1.552–4.121;
P¼0.0003), especially in patients diag-
nosed under 50 years of age (OR 3.443,
95% CI (1.862–6.367); P¼0.0002) (Deb-
niak et al., 2005). Harland et al. (2000)
demonstrated a linkage disequilibrium of
the A148T allele with the 493A4T
CDKN2A promoter variant, known to
affect gene expression, which might be
involved in melanoma susceptibility.
In our study, no significant differ-
ence of the A148T allele frequency was
observed between melanoma patients
and controls in the French and Italian
populations, although the allele
frequency was significantly different
between these populations.
In conclusion, our results showed
that the A148T allele is not associated
with the risk of cutaneous melanoma
nor with the age at melanoma diagnosis
in the French and Italian populations.
Assessment of this allele in other
populations should further help to
clarify the role of the A148T variant in
melanoma predisposition.
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TO THE EDITOR
The phosphatidylinositol 3-kinase
(PI3K) pathway plays an important role
in regulating cellular growth, prolifera-
tion, survival, and migration. The PI3K
complex is a direct target of activated
RAS (Rodriguez-Viciana et al., 1994)
and is negatively regulated by the lipid
phosphatase phosphatidylinositol-3,4,5-
trisphosphate 3-phosphatase (PTEN)
(Stambolic et al., 1998; Stahl et al.,
2003). The PI3K complex phosphory-
lates and activates the v-akt murine
thymoma viral oncogene homologs
(AKT) (Franke et al., 1997), which are
activated in many melanomas and
associated with poor prognosis (Dhawan
et al., 2002). Common routes to PI3K
pathway activation in melanoma are
mutation of neuroblastoma ras viral
oncogene homolog (NRAS) (Albino
et al., 1989; vanElsas et al., 1996) and
deletion or mutation of PTEN (Herbst
et al., 1994; Guldberg et al., 1997;
Bastian et al., 1998; Robertson et al.,
1998; Pollock et al., 2002). PTEN
inactivation is frequent in melanomas
with mutation of BRAF, but not in
melanomas with mutation of NRAS
(Tsao et al., 2004; Curtin et al., 2005),
suggesting that activation of the PI3K
pathway cooperates with genetic altera-
tions of the mitogen-activated protein
kinase pathway in melanoma. In our
previous study some melanomas
showed increased expression levels
of phospho-AKT but did not show
mutations in NRAS or loss of PTEN
(Curtin et al., 2005), suggesting that
additional genetic aberrations may
be present upstream of AKT in the
PI3K pathway. Recent reports indicate
that phosphatidylinositol 3-kinase, cata-
lytic, alpha (PIK3CA) is frequently
mutated in other cancers (Samuels
et al., 2004). We sought to assess the
mutational status of components of the
PI3K complex in a panel of 118 primary
melanomas and in 34 melanoma cell
lines.
We analyzed DNA extracted from
archival paraffin-embedded primary
melanomas with an invasive compo-
nent in which tumor cells predomi-
nated over stroma cells that in part
were previously analyzed and reported
(Curtin et al., 2005). The study was
approved by the Institutional Review
Board of the University of California,
San Francisco. The study compared
DNA from tumors selected to obtain
five groups of comparable sizes: 34
acral melanomas from the palms, soles,
and subungual sites; 17 mucosal mela-
nomas; 13 desmoplastic melanomas;
26 melanomas from chronically sun-
damaged skin and 28 melanoma from
skin without chronic sun damage (non-
chronically sun-damaged skin). Chroni-
cally sun-damaged skin was defined by
the microscopic presence or absence of
marked solar elastosis of the dermis
surrounding the melanomas. In all but
a few cases, chronically sun-damaged
skin melanoma occurred on the face
and non-chronically sun-damaged skin
melanoma occurred on the trunk and
extremities.
Exons of interest were amplified by
PCR and sequenced as described pre-
viously (Curtin et al., 2005) using
Abbreviations: AKT, v-akt murine thymoma viral oncogene homolog; PI3K, phosphatidylinositol
3-kinase; PIK3CA, phosphatidylinositol 3-kinase, catalytic, alpha; PIK3CB, phosphatidylinositol 3-kinase,
catalytic, beta; PIK3CD, phosphatidylinositol 3-kinase, catalytic, delta; PIK3R1, phosphatidylinositol
3-kinase, regulatory, 1; PIK3R2, phosphatidylinositol 3-kinase, regulatory, 2; PIK3R3, phosphatidylino-
sitol 3-kinase, regulatory, 3; PTEN, phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase; NRAS,
neuroblastoma ras viral oncogene homolog
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